Novartis AG

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article Defining immune reset: achieving sustained remission in autoimmune diseases (2025) Junt T, Calzascia T, Traggiai E, da Costa AN, Gergely P, Schett G, Dörner T, Siegel RM Journal article Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer (2024) Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, Schneeweiss A, et al. Journal article Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device (2024) Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Soltani A, et al. Journal article Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158) (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article, Erratum Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study (2024) Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, et al. Journal article 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop (2024) Whittaker JL, Kalsoum R, Bilzon J, Conaghan PG, Crossley K, Dodge GR, Getgood A, et al. Journal article CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs (2024) Schneeweiss A, Brucker SY, Hübner H, Volmer LL, Hack C, Seitz K, Rübner M, et al. Journal article, Review article